Literature DB >> 8947520

Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.

D Vageli1, H Kiaris, D Delakas, P Anezinis, A Cranidis, D A Spandidos.   

Abstract

In this study we demonstrate the involvement of ras oncogenes in bladder cancer at the level of RNA overexpression. We examined 26 bladder specimens, consisting of paired tumor and adjacent normal tissue and found that H-ras transcripts were overexpressed in 39% of the specimens while K-ras and N-ras in 58% of total specimens. Each tumor specimen had a unique pattern of overexpression for the three ras genes. A competitive-RT-PCR was employed for H-ras and a beta-actin control gene was co-amplified with K-ras or N-ras genes. These results indicate that the involvement of ras oncogenes in bladder cancer could be relative to overexpression of these genes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947520     DOI: 10.1016/0304-3835(96)04372-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.

Authors:  A Rose; M Grandoch; F vom Dorp; H Rübben; A Rosenkranz; J W Fischer; A-A Weber
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

Review 3.  Incorporating VEGF-targeted therapy in advanced urothelial cancer.

Authors:  Sujata Narayanan; Sandy Srinivas
Journal:  Ther Adv Med Oncol       Date:  2016-09-16       Impact factor: 8.168

4.  Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9).

Authors:  Jorunn Litlekalsoy; Jens G Hostmark; Daniela Elena Costea; Martin Illemann; Ole Didrik Laerum
Journal:  Virchows Arch       Date:  2012-10-06       Impact factor: 4.064

5.  Nucleic Acid Targeted Therapy: G4 Oligonucleotides Downregulate HRAS in Bladder Cancer Cells through a Decoy Mechanism.

Authors:  Giulia Miglietta; Alaa S Gouda; Susanna Cogoi; Erik B Pedersen; Luigi E Xodo
Journal:  ACS Med Chem Lett       Date:  2015-10-18       Impact factor: 4.345

6.  Gene expression profiling of chemically induced rat bladder tumors.

Authors:  Ruisheng Yao; Yijun Yi; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

7.  Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.

Authors:  Kiran Tripathi; Apul Goel; Atin Singhai; Minal Garg
Journal:  Mol Biol Rep       Date:  2021-02-23       Impact factor: 2.316

8.  Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium.

Authors:  Dimitra P Vageli; Stavros Giannopoulos; Sotirios G Doukas; Christos Kalaitzis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; George K Koukoulis; Stavros Touloupidis
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

9.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

10.  HRAS is silenced by two neighboring G-quadruplexes and activated by MAZ, a zinc-finger transcription factor with DNA unfolding property.

Authors:  Susanna Cogoi; Andrey E Shchekotikhin; Luigi E Xodo
Journal:  Nucleic Acids Res       Date:  2014-07-10       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.